Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: Martin Bucksbaum Distinguished University Chair, Professor and Director
The Hybrid Approach in CAD with Restore® DEB
Author(s): Alfonso Ielasi Added: 10 months ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more

Intervention
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Felicita Andreotti , Diana Gorog , Marco Valgimigli , et al Start date: Dec 14, 2023
This live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), will demonstrate how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Join key opinion leadersProf Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese (University of Sassari,… View more

Anticoagulation
ESC 24: NOTION-3: FFR Guided PCI in TAVI
Author(s): Jacob Thomsen Lønborg Added: 7 months ago
ESC Congress 2024 — FFR-guided PCI improves outcomes in TAVI patients with coronary artery disease.Principal investigator, Prof Jacob Thomsen Lønborg (Rigshospitalet, DK) joins us to discuss the NOTION-3 trial (NCT03058627). A multinational, open-label, investigator-initiated trial evaluated the efficacy of FFR-guided PCI versus medical therapy in managing coronary artery disease (CAD) among… View more

Imaging & Diagnostics

Intervention
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 3 weeks ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
ESC 23: The OCTIVUS Study
Author(s): Duk-Woo Park , Do-Yoon Kang Added: 1 year ago
ESC 2023 — We are joined onsite by Dr Duk-Woo Park and Dr Do-Yoon Kang (Asan Medical Center, Seoul, KR) to discuss the findings from the OCTIVUS study (NCT03394079). The OCTIVUS study (Seung-Jung Park, CardioVascular Research Foundation, Korea) aims to compare the clinical safety and efficacy of optimal coherence tomography (OCT) guided and intravascular ultrasound (IVUS) guided strategies in… View more

Intervention
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 7 months ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 1 year ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more

Anticoagulation
Research Area(s) / Expertise: Job title: Professor of Medicine
Dr. William E. Boden is Professor of Medicine at Boston University School of Medicine and Lecturer in Medicine, Harvard Medical School, in Boston, Massachusetts. In July 2016, Dr. Boden returned to the VA Boston Healthcare System to assume new duties as the Physician Research Lead for the New England VA Healthcare System and as the Scientific Director of the Clinical Trials Network, which is… View more
The FISH&CHIPS Study: Real-world Study Reveals Significant Reduction in All-cause and Cardiovascular Mortality
Author(s): Jonathon A Leipsic Added: 1 year ago
FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).A 14%… View more

Guidelines & Statements

Imaging & Diagnostics